The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2 …
…, IM Bondarenko, SO Kulyk, J Ettl, R Patel… - The lancet …, 2015 - thelancet.com
Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent
kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen …
kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory activity in oestrogen …
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
…, S Berry, CM Gomez, D Dammrich, R Patel… - The Lancet …, 2019 - thelancet.com
Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
[HTML][HTML] Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded …
…, IM Bondarenko, I Lang, T Pinter, K Boer, R Patel… - Breast Cancer …, 2016 - Springer
Background Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4
and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in …
and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in …
[HTML][HTML] Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+ …
RS Finn, K Boer, I Bondarenko, R Patel, T Pinter… - Breast cancer research …, 2020 - Springer
Purpose Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in
combination with endocrine therapy for the treatment of women and men with hormone receptor–…
combination with endocrine therapy for the treatment of women and men with hormone receptor–…
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
…, J Sanchez, DPS Sohal, J Strickler, R Patel… - Cancer …, 2019 - Wiley Online Library
Purpose Notch signaling dysregulation is implicated in the development of pancreatic
adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 …
adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 …
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2 …
…, I Lang, K Boer, I Bondarenko, SO Kulyk, J Ettl, R Patel… - 2017 - ascopubs.org
1001 Background: Preclinical data identified a synergistic role for P and hormone blockade
in blocking growth of ER+ breast cancer (BC) cell lines. PALOMA-1 was an open-label …
in blocking growth of ER+ breast cancer (BC) cell lines. PALOMA-1 was an open-label …
[HTML][HTML] Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US …
…, GR Bean, R Dichmann, A Perez, R Patel… - Nature …, 2020 - nature.com
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …
NATALEE: Phase III study of ribociclib (RIBO)+ endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor …
DJ Slamon, PA Fasching, R Patel, S Verma, SA Hurvitz… - 2019 - ascopubs.org
TPS597 Background: RIBO is a selective inhibitor of CDK4/6 with demonstrated efficacy and
is well tolerated when combined with ET in pre-/peri- and postmenopausal women with HR+…
is well tolerated when combined with ET in pre-/peri- and postmenopausal women with HR+…
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+ …
…, JW Leach, J Sanchez, D Sohal, JH Strickler, R Patel… - 2017 - ascopubs.org
279 Background: Tarextumab (TRXT), fully human IgG2 antibody inhibits signaling of
Notch2/ 3 receptors. Tumor regression seen in Notch3 (N3) expressing pt-derived pancreatic …
Notch2/ 3 receptors. Tumor regression seen in Notch3 (N3) expressing pt-derived pancreatic …
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole …
…, K Boer, IM Bondarenko, SO Kulyk, J Ettl, R Patel… - Cancer Research, 2014 - AACR
Background: PD 0332991 (palbociclib), a selective inhibitor of CDK-4/6, prevents DNA
synthesis by blocking cell cycle progression. Preclinical studies identified luminal ER+ breast …
synthesis by blocking cell cycle progression. Preclinical studies identified luminal ER+ breast …
